Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

AstraZeneca Donates $27.6 Million Worth Of Iressa To China

This article was originally published in PharmAsia News

Executive Summary

AstraZeneca is donating $27.6 million worth of its Iressa (gefitinib) cancer drug to a Chinese foundation to distribute to needy cancer patients. The China Charity Federation already has distributed $10 million worth of the tablets to patients with advanced non-small cell lung cancer and plans to distribute the rest this year. A vice president of the Anglo-Swedish AstraZeneca announced the gift at a ceremony in Beijing. The drug is available to those who have had at least one chemotherapy treatment and have used Iressa for at least six months before applying for the free tablets. (Click here for more

Table

View full table

Tags:
Latest Headlines

Humira Market Erosion Is Continuing As Expected, AbbVie Says

Pfizer Matches Beqvez Price To Hemgenix In Hemophilia B, Plans Warranty Program

Analysis: Novo And Lilly Make Their Money Work

AstraZeneca’s Hot Streak Whets Investor Appetite For What’s Next

See All
UsernamePublicRestriction

Register

SC066694

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By